Srivastava R N, Agarwal R K, Moudgil A, Bhuyan U N
J Pediatr. 1986 Jan;108(1):66-70. doi: 10.1016/s0022-3476(86)80770-3.
Corticosteroid resistance appeared late in the course of relapsing nephrotic syndrome in 12 patients who previously had steroid-sensitive relapses for 0.8 to 13 years. In 11 patients, renal histology performed earlier in the course of the disease showed minimal change in eight, mesangial proliferative glomerulonephritis (MesPGN) in two, and focal segmental glomerulosclerosis (FSGS) in one. Renal biopsy in another patient and a repeat procedure in four of eight patients who initially showed minimal change was done after they had developed steroid resistance, and showed FSGS. Cyclophosphamide was given to 11 patients after they became steroid resistant, and induced remission in eight that continued for 1 to 2 years in two patients. The other six had relapses that were steroid sensitive, but three of them (two with FSGS and one with MesPGN) later became resistant to steroids as well as to cyclophosphamide. Of six patients with FSGS, four with initial or subsequent resistance to cyclophosphamide eventually developed renal insufficiency. The other two have remained in remission for 12 to 16 years; one of these did not receive cyclophosphamide. Our observations suggest that patients with late steroid resistance comprise a heterogeneous group; those with FSGS and resistance to cyclophosphamide therapy may have a poor outcome.
12例复发性肾病综合征患者在病程后期出现皮质类固醇抵抗,这些患者此前曾有0.8至13年的类固醇敏感复发史。11例患者在病程早期进行的肾组织学检查显示,8例为微小病变,2例为系膜增生性肾小球肾炎(MesPGN),1例为局灶节段性肾小球硬化(FSGS)。另1例患者以及最初表现为微小病变的8例患者中的4例在出现类固醇抵抗后进行了肾活检,结果显示为FSGS。11例患者在出现类固醇抵抗后接受了环磷酰胺治疗,其中8例诱导缓解,2例缓解持续1至2年。另外6例复发对类固醇敏感,但其中3例(2例FSGS和1例MesPGN)后来对类固醇和环磷酰胺均产生抵抗。6例FSGS患者中,4例最初或随后对环磷酰胺抵抗,最终发展为肾功能不全。另外2例已缓解12至16年;其中1例未接受环磷酰胺治疗。我们的观察结果表明,晚期类固醇抵抗患者构成一个异质性群体;那些患有FSGS且对环磷酰胺治疗抵抗的患者可能预后不良。